{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T10:54:44Z","timestamp":1792580084236,"version":"4.5.0"},"reference-count":127,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T00:00:00Z","timestamp":1710806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T00:00:00Z","timestamp":1710806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The 9th Cardiovascular Outcome Trial (CVOT) Summit: Congress on Cardiovascular, Kidney, and Metabolic Outcomes was held virtually on November 30-December 1, 2023. This reference congress served as a platform for in-depth discussions and exchange on recently completed outcomes trials including dapagliflozin (DAPA-MI), semaglutide (SELECT and STEP-HFpEF) and bempedoic acid (CLEAR Outcomes), and the advances they represent in reducing the risk of major adverse cardiovascular events (MACE), improving metabolic outcomes, and treating obesity-related heart failure with preserved ejection fraction (HFpEF). A broad audience of endocrinologists, diabetologists, cardiologists, nephrologists and primary care physicians participated in online discussions on guideline updates for the management of cardiovascular disease (CVD) in diabetes, heart failure (HF) and chronic kidney disease (CKD); advances in the management of type 1 diabetes (T1D) and its comorbidities; advances in the management of CKD with SGLT2 inhibitors and non-steroidal mineralocorticoid receptor antagonists (nsMRAs); and advances in the treatment of obesity with GLP-1 and dual GIP\/GLP-1 receptor agonists. The association of diabetes and obesity with nonalcoholic steatohepatitis (NASH; metabolic dysfunction-associated steatohepatitis, MASH) and cancer and possible treatments for these complications were also explored. It is generally assumed that treatment of chronic diseases is equally effective for all patients. However, as discussed at the Summit, this assumption may not be true. Therefore, it is important to enroll patients from diverse racial and ethnic groups in clinical trials and to analyze patient-reported outcomes to assess treatment efficacy, and to develop innovative approaches to tailor medications to those who benefit most with minimal side effects. Other keys to a successful management of diabetes and comorbidities, including dementia, entail the use of continuous glucose monitoring (CGM) technology and the implementation of appropriate patient-physician communication strategies. The 10th Cardiovascular Outcome Trial Summit will be held virtually on December 5\u20136, 2024 (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.cvot.org\">http:\/\/www.cvot.org<\/jats:ext-link>).<\/jats:p>","DOI":"10.1186\/s12933-024-02180-8","type":"journal-article","created":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T16:02:34Z","timestamp":1710864154000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes"],"prefix":"10.1186","volume":"23","author":[{"given":"Oliver","family":"Schnell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine","family":"Barnard-Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadej","family":"Battelino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Ceriello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena Elding","family":"Larsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Fern\u00e1ndez-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Forst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan-Pablo","family":"Frias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"James R.","family":"Gavin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Giorgino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per-Henrik","family":"Groop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiddo J. L.","family":"Heerspink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Herzig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hummel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Huntley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baruch","family":"Itzhak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linong","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail","family":"Kosiborod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nebosja","family":"Lalic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Macieira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayaz A.","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Mankovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaus","family":"Marx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Mathieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timo D.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kausik","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena W.","family":"Rodbard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Rossing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Ryd\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra-Maria","family":"Schumm-Draeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"\u0160krha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Snoek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Tacke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta Tendal","family":"Jeppesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solomon","family":"Tesfaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinar","family":"Topsever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Vilsb\u00f8ll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefeng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eberhard","family":"Standl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,19]]},"reference":[{"key":"2180_CR1","doi-asserted-by":"publisher","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","volume":"183","author":"H Sun","year":"2022","unstructured":"Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119.","journal-title":"Diabetes Res Clin Pract"},{"key":"2180_CR2","unstructured":"Federation WO. World Obesity Atlas 2023. 2023."},{"issue":"1","key":"2180_CR3","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12933-018-0728-6","volume":"17","author":"TR Einarson","year":"2018","unstructured":"Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007\u20132017. Cardiovasc Diabetol. 2018;17(1):83.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2180_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1614362","volume":"377","author":"A Afshin","year":"2017","unstructured":"Afshin A, Forouzanfar MH, Reitsma MB, Sur P, Estep K, Lee A, et al. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017;377(1):13\u201327.","journal-title":"N Engl J Med"},{"issue":"1","key":"2180_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s43441-020-00211-6","volume":"55","author":"J Rick Turner","year":"2021","unstructured":"Rick Turner J. FDA\u2019s New Guidance for Industry addressing evaluation of the safety of new drugs for improving Glycemic Control: a Case Study in Regulatory Science. Ther Innov Regul Sci. 2021;55(1):1\u20135.","journal-title":"Ther Innov Regul Sci"},{"key":"2180_CR6","unstructured":"FDA. Guidance for Industry Diabetes Mellitus - Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes - Guidance Document2008. Available from: https:\/\/www.regulations.gov\/document\/FDA-2008-D-0118-0029."},{"issue":"12","key":"2180_CR7","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.2215\/CJN.11491116","volume":"12","author":"RZ Alicic","year":"2017","unstructured":"Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, Progress, and possibilities. Clin J Am Soc Nephrology: CJASN. 2017;12(12):2032\u201345.","journal-title":"Clin J Am Soc Nephrology: CJASN"},{"issue":"1","key":"2180_CR8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2337\/dci20-0050","volume":"44","author":"American Diabetes Association","year":"2021","unstructured":"American Diabetes Association. Standards of medical care in diabetes\u20142021. Diabetes Care. 2021;44(1):1\u2013S232.","journal-title":"Diabetes Care"},{"issue":"2","key":"2180_CR9","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.kint.2017.01.030","volume":"92","author":"CP Wen","year":"2017","unstructured":"Wen CP, Chang CH, Tsai MK, Lee JH, Lu PJ, Tsai SP, et al. Diabetes with early kidney involvement may shorten life expectancy by 16 years. Kidney Int. 2017;92(2):388\u201396.","journal-title":"Kidney Int"},{"issue":"5","key":"2180_CR10","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/ejhf.1170","volume":"20","author":"PM Seferovi\u0107","year":"2018","unstructured":"Seferovi\u0107 PM, Petrie MC, Filippatos GS, Anker SD, Rosano G, Bauersachs J, et al. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018;20(5):853\u201372.","journal-title":"Eur J Heart Fail"},{"issue":"14","key":"2180_CR11","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","volume":"369","author":"BM Scirica","year":"2013","unstructured":"Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317\u201326.","journal-title":"N Engl J Med"},{"issue":"14","key":"2180_CR12","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","volume":"369","author":"WB White","year":"2013","unstructured":"White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327\u201335.","journal-title":"N Engl J Med"},{"issue":"3","key":"2180_CR13","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1056\/NEJMoa1501352","volume":"373","author":"JB Green","year":"2015","unstructured":"Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of Sitagliptin on Cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232\u201342.","journal-title":"N Engl J Med"},{"issue":"1","key":"2180_CR14","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1001\/jama.2018.18269","volume":"321","author":"J Rosenstock","year":"2019","unstructured":"Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, et al. Effect of Linagliptin vs Placebo on Major Cardiovascular events in adults with type 2 diabetes and High Cardiovascular and renal risk: the CARMELINA Randomized Clinical Trial. JAMA. 2019;321(1):69\u201379.","journal-title":"JAMA"},{"issue":"12","key":"2180_CR15","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1001\/jama.2019.13772","volume":"322","author":"J Rosenstock","year":"2019","unstructured":"Rosenstock J, Kahn SE, Johansen OE, Zinman B, Espeland MA, Woerle HJ, et al. Effect of Linagliptin vs glimepiride on major adverse Cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA Randomized Clinical Trial. JAMA. 2019;322(12):1155\u201366.","journal-title":"JAMA"},{"issue":"23","key":"2180_CR16","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","volume":"373","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, K\u00f8ber LV, et al. Lixisenatide in patients with type 2 diabetes and Acute Coronary Syndrome. N Engl J Med. 2015;373(23):2247\u201357.","journal-title":"N Engl J Med"},{"issue":"19","key":"2180_CR17","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, J\u00f3dar E, Leiter LA, et al. Semaglutide and Cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834\u201344.","journal-title":"N Engl J Med"},{"issue":"4","key":"2180_CR18","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and Cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311\u201322.","journal-title":"N Engl J Med"},{"issue":"13","key":"2180_CR19","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","volume":"377","author":"RR Holman","year":"2017","unstructured":"Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, et al. Effects of once-weekly Exenatide on Cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377(13):1228\u201339.","journal-title":"N Engl J Med"},{"issue":"10157","key":"2180_CR20","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","volume":"392","author":"AF Hernandez","year":"2018","unstructured":"Hernandez AF, Green JB, Janmohamed S, D\u2019Agostino RB, Sr., Granger CB, Jones NP, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (harmony outcomes): a double-blind, randomised placebo-controlled trial. Lancet (London England). 2018;392(10157):1519\u201329.","journal-title":"Lancet (London England)"},{"issue":"10","key":"2180_CR21","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa2108269","volume":"385","author":"HC Gerstein","year":"2021","unstructured":"Gerstein HC, Sattar N, Rosenstock J, Ramasundarahettige C, Pratley R, Lopes RD, et al. Cardiovascular and renal outcomes with Efpeglenatide in Type 2 diabetes. N Engl J Med. 2021;385(10):896\u2013907.","journal-title":"N Engl J Med"},{"issue":"7","key":"2180_CR22","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and Cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644\u201357.","journal-title":"N Engl J Med"},{"issue":"4","key":"2180_CR23","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and Cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347\u201357.","journal-title":"N Engl J Med"},{"issue":"22","key":"2180_CR24","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"15","key":"2180_CR25","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","volume":"383","author":"CP Cannon","year":"2020","unstructured":"Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, et al. Cardiovascular outcomes with Ertugliflozin in Type 2 diabetes. N Engl J Med. 2020;383(15):1425\u201335.","journal-title":"N Engl J Med"},{"issue":"2","key":"2180_CR26","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa2030186","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2021;384(2):129\u201339.","journal-title":"N Engl J Med"},{"issue":"21","key":"2180_CR27","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995\u20132008.","journal-title":"N Engl J Med"},{"issue":"15","key":"2180_CR28","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with Empagliflozin in Heart failure. N Engl J Med. 2020;383(15):1413\u201324.","journal-title":"N Engl J Med"},{"issue":"2","key":"2180_CR29","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2030183","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384(2):117\u201328.","journal-title":"N Engl J Med"},{"issue":"16","key":"2180_CR30","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, B\u00f6hm M, et al. Empagliflozin in Heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451\u201361.","journal-title":"N Engl J Med"},{"issue":"12","key":"2180_CR31","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in Heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089\u201398.","journal-title":"N Engl J Med"},{"issue":"24","key":"2180_CR32","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306.","journal-title":"N Engl J Med"},{"issue":"15","key":"2180_CR33","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436\u201346.","journal-title":"N Engl J Med"},{"issue":"2","key":"2180_CR34","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"WG Herrington","year":"2023","unstructured":"Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117\u201327.","journal-title":"N Engl J Med"},{"issue":"24","key":"2180_CR35","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385(24):2252\u201363.","journal-title":"N Engl J Med"},{"issue":"23","key":"2180_CR36","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of Finerenone on chronic kidney Disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219\u201329.","journal-title":"N Engl J Med"},{"issue":"11","key":"2180_CR37","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.jchf.2022.07.013","volume":"10","author":"G Filippatos","year":"2022","unstructured":"Filippatos G, Anker SD, Pitt B, Rossing P, Joseph A, Kolkhof P, et al. Finerenone and Heart failure outcomes by kidney Function\/Albuminuria in chronic kidney disease and diabetes. JACC Heart Fail. 2022;10(11):860\u201370.","journal-title":"JACC Heart Fail"},{"key":"2180_CR38","doi-asserted-by":"crossref","unstructured":"James S, Erlinge D, Storey RF, McGuire DK, Belder Md, Eriksson N, et al. Dapagliflozin in myocardial infarction without diabetes or heart failure. NEJM Evid. 2024;3:EVIDoa2300286.","DOI":"10.1056\/EVIDoa2300286"},{"issue":"11","key":"2180_CR39","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989\u20131002.","journal-title":"N Engl J Med"},{"issue":"10278","key":"2180_CR40","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","volume":"397","author":"M Davies","year":"2021","unstructured":"Davies M, F\u00e6rch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, et al. Semaglutide 2\u00b74\u00a0mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet (London England). 2021;397(10278):971\u201384.","journal-title":"Lancet (London England)"},{"issue":"14","key":"2180_CR41","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1001\/jama.2021.1831","volume":"325","author":"TA Wadden","year":"2021","unstructured":"Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, et al. Effect of Subcutaneous Semaglutide vs Placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 Randomized Clinical Trial. JAMA. 2021;325(14):1403\u201313.","journal-title":"JAMA"},{"issue":"14","key":"2180_CR42","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/jama.2021.3224","volume":"325","author":"D Rubino","year":"2021","unstructured":"Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, et al. Effect of continued Weekly Subcutaneous Semaglutide vs Placebo on Weight loss maintenance in adults with overweight or obesity: the STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1414\u201325.","journal-title":"JAMA"},{"issue":"10295","key":"2180_CR43","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","volume":"398","author":"J Rosenstock","year":"2021","unstructured":"Rosenstock J, Wysham C, Fr\u00edas JP, Kaneko S, Lee CJ, Fern\u00e1ndez Land\u00f3 L, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet (London England). 2021;398(10295):143\u201355.","journal-title":"Lancet (London England)"},{"issue":"6","key":"2180_CR44","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Fr\u00edas","year":"2021","unstructured":"Fr\u00edas JP, Davies MJ, Rosenstock J, P\u00e9rez Manghi FC, Fern\u00e1ndez Land\u00f3 L, Bergman BK, et al. Tirzepatide versus Semaglutide once Weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503\u201315.","journal-title":"N Engl J Med"},{"issue":"10300","key":"2180_CR45","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","volume":"398","author":"B Ludvik","year":"2021","unstructured":"Ludvik B, Giorgino F, J\u00f3dar E, Frias JP, Fern\u00e1ndez Land\u00f3 L, Brown K, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet (London England). 2021;398(10300):583\u201398.","journal-title":"Lancet (London England)"},{"issue":"10313","key":"2180_CR46","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","volume":"398","author":"S Del Prato","year":"2021","unstructured":"Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet (London England). 2021;398(10313):1811\u201324.","journal-title":"Lancet (London England)"},{"issue":"6","key":"2180_CR47","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1001\/jama.2022.0078","volume":"327","author":"D Dahl","year":"2022","unstructured":"Dahl D, Onishi Y, Norwood P, Huh R, Bray R, Patel H, et al. Effect of Subcutaneous Tirzepatide vs Placebo added to titrated insulin glargine on Glycemic Control in patients with type 2 diabetes: the SURPASS-5 Randomized Clinical Trial. JAMA. 2022;327(6):534\u201345.","journal-title":"JAMA"},{"issue":"3","key":"2180_CR48","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once Weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205\u201316.","journal-title":"N Engl J Med"},{"issue":"24","key":"2180_CR49","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and Cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221\u201332.","journal-title":"N Engl J Med"},{"issue":"12","key":"2180_CR50","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069\u201384.","journal-title":"N Engl J Med"},{"issue":"3","key":"2180_CR51","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s13679-023-00518-z","volume":"12","author":"J Vekic","year":"2023","unstructured":"Vekic J, Stefanovic A, Zeljkovic A. Obesity and dyslipidemia: a review of current evidence. Curr Obes Rep. 2023;12(3):207\u201322.","journal-title":"Curr Obes Rep"},{"issue":"9976","key":"2180_CR52","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/S0140-6736(14)61368-4","volume":"385","author":"J Fulcher","year":"2015","unstructured":"Fulcher J, O\u2019Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet (London England). 2015;385(9976):1397\u2013405.","journal-title":"Lancet (London England)"},{"issue":"17","key":"2180_CR53","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","volume":"36","author":"ES Stroes","year":"2015","unstructured":"Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, et al. Statin-associated muscle symptoms: impact on statin therapy-european Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015;36(17):1012\u201322.","journal-title":"Eur Heart J"},{"key":"2180_CR54","doi-asserted-by":"publisher","first-page":"13457","DOI":"10.1038\/ncomms13457","volume":"7","author":"SL Pinkosky","year":"2016","unstructured":"Pinkosky SL, Newton RS, Day EA, Ford RJ, Lhotak S, Austin RC, et al. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nat Commun. 2016;7:13457.","journal-title":"Nat Commun"},{"issue":"15","key":"2180_CR55","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","volume":"388","author":"SE Nissen","year":"2023","unstructured":"Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, et al. Bempedoic Acid and Cardiovascular outcomes in statin-intolerant patients. N Engl J Med. 2023;388(15):1353\u201364.","journal-title":"N Engl J Med"},{"key":"2180_CR56","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12933-016-0357-x","volume":"15","author":"O Schnell","year":"2016","unstructured":"Schnell O, Standl E, Catrinoiu D, Genovese S, Lalic N, Skra J, et al. Report from the 1st Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group. Cardiovasc Diabetol. 2016;15:33.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2180_CR57","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12933-017-0508-8","volume":"16","author":"O Schnell","year":"2017","unstructured":"Schnell O, Standl E, Catrinoiu D, Genovese S, Lalic N, Skra J, et al. Report from the 2nd Cardiovascular Outcome Trial (CVOT) Summit of the diabetes and Cardiovascular Disease (D&CVD) EASD Study Group. Cardiovasc Diabetol. 2017;16(1):35.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2180_CR58","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12933-018-0667-2","volume":"17","author":"O Schnell","year":"2018","unstructured":"Schnell O, Standl E, Catrinoiu D, Genovese S, Lalic N, Lalic K, et al. Report from the 3rd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group. Cardiovasc Diabetol. 2018;17(1):30.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2180_CR59","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12933-019-0822-4","volume":"18","author":"O Schnell","year":"2019","unstructured":"Schnell O, Standl E, Catrinoiu D, Itzhak B, Lalic N, Rahelic D, et al. Report from the 4th Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group. Cardiovasc Diabetol. 2019;18(1):30.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2180_CR60","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12933-020-01022-7","volume":"19","author":"O Schnell","year":"2020","unstructured":"Schnell O, Standl E, Cos X, Heerspink HJ, Itzhak B, Lalic N, et al. Report from the 5th cardiovascular outcome trial (CVOT) summit. Cardiovasc Diabetol. 2020;19(1):47.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2180_CR61","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12933-021-01254-1","volume":"20","author":"O Schnell","year":"2021","unstructured":"Schnell O, Cos X, Cosentino F, Forst T, Giorgino F, Heersprink HJL, et al. Report from the CVOT Summit 2020: new cardiovascular and renal outcomes. Cardiovasc Diabetol. 2021;20(1):75.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2180_CR62","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12933-022-01481-0","volume":"21","author":"O Schnell","year":"2022","unstructured":"Schnell O, Battelino T, Bergenstal R, Bl\u00fcher M, B\u00f6hm M, Brosius F, et al. Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes. Cardiovasc Diabetol. 2022;21(1):50.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2180_CR63","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12933-023-01788-6","volume":"22","author":"O Schnell","year":"2023","unstructured":"Schnell O, Battelino T, Bergenstal R, Birkenfeld AL, Ceriello A, Cheng A, et al. CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes. Cardiovasc Diabetol. 2023;22(1):59.","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"2180_CR64","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1093\/eurheartj\/ehr352","volume":"33","author":"SJ Pocock","year":"2011","unstructured":"Pocock SJ, Ariti CA, Collier TJ, Wang D. The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities. Eur Heart J. 2011;33(2):176\u201382.","journal-title":"Eur Heart J"},{"issue":"1","key":"2180_CR65","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1186\/s12933-023-01993-3","volume":"22","author":"A Ceriello","year":"2023","unstructured":"Ceriello A, Rodbard HW, Battelino T, Brosius F, Cosentino F, Green J, et al. Data from network meta-analyses can inform clinical practice guidelines and decision-making in diabetes management: perspectives of the taskforce of the guideline workshop. Cardiovasc Diabetol. 2023;22(1):277.","journal-title":"Cardiovasc Diabetol"},{"key":"2180_CR66","first-page":"e074068","volume":"381","author":"Q Shi","year":"2023","unstructured":"Shi Q, Nong K, Vandvik PO, Guyatt GH, Schnell O, Ryd\u00e9n L, et al. Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ (Clinical Res ed). 2023;381:e074068.","journal-title":"BMJ (Clinical Res ed)"},{"issue":"7889","key":"2180_CR67","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/d41586-021-03690-1","volume":"600","author":"J Elliott","year":"2021","unstructured":"Elliott J, Lawrence R, Minx JC, Oladapo OT, Ravaud P, Tendal Jeppesen B, et al. Decision makers need constantly updated evidence synthesis. Nature. 2021;600(7889):383\u20135.","journal-title":"Nature"},{"issue":"37","key":"2180_CR68","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","volume":"44","author":"TA McDonagh","year":"2023","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, et al. 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(37):3627\u201339.","journal-title":"Eur Heart J"},{"issue":"39","key":"2180_CR69","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","volume":"44","author":"N Marx","year":"2023","unstructured":"Marx N, Federici M, Sch\u00fctt K, M\u00fcller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043\u2013140.","journal-title":"Eur Heart J"},{"key":"2180_CR70","doi-asserted-by":"crossref","unstructured":"Kunutsor SK, Khunti K, Seidu S. Racithnic and regional differences in the effect of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists on cardiovascular and renal outcomes: a systematic review and meta-analysis of cardiovascular outcome trials. J R Soc Med. 2023:1410768231198442.","DOI":"10.1177\/01410768231198442"},{"key":"2180_CR71","doi-asserted-by":"crossref","unstructured":"Kelly RC, Holt RIG, Desborough L, Majidi S, Town M, Naranjo D et al. The psychosocial burdens of living with diabetes. Diabet Medicine: J Br Diabet Association. 2023:e15219.","DOI":"10.1111\/dme.15219"},{"key":"2180_CR72","unstructured":"Federation ID. IDF Annual Report 2022. 2022."},{"issue":"1","key":"2180_CR73","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","volume":"12","author":"CP Kovesdy","year":"2022","unstructured":"Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl (2011). 2022;12(1):7\u201311.","journal-title":"Kidney Int Suppl (2011)"},{"issue":"10225","key":"2180_CR74","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","volume":"395","author":"GCKD Collaboration","year":"2020","unstructured":"Collaboration GCKD. Global, regional, and national burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the global burden of Disease Study 2017. Lancet (London England). 2020;395(10225):709\u201333.","journal-title":"Lancet (London England)"},{"issue":"12","key":"2180_CR75","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.2337\/dci22-0027","volume":"45","author":"IH de Boer","year":"2022","unstructured":"de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM, et al. Diabetes management in chronic kidney disease: a Consensus Report by the American Diabetes Association (ADA) and kidney disease: improving global outcomes (KDIGO). Diabetes Care. 2022;45(12):3075\u201390.","journal-title":"Diabetes Care"},{"issue":"1","key":"2180_CR76","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.pcd.2022.11.013","volume":"17","author":"S Seidu","year":"2023","unstructured":"Seidu S, Cos X, Topsever P. Self-rated knowledge and competence regarding the management of chronic kidney disease in primary care: a cross-sectional European survey of primary care professionals. Prim Care Diabetes. 2023;17(1):19\u201326.","journal-title":"Prim Care Diabetes"},{"issue":"2","key":"2180_CR77","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1177\/19322968211054520","volume":"17","author":"B Schultes","year":"2023","unstructured":"Schultes B, Emmerich S, Kistler AD, Mecheri B, Schnell O, Rudofsky G. Impact of albumin-to-creatinine ratio point-of-care testing on the diagnosis and management of Diabetic kidney disease. J Diabetes Sci Technol. 2023;17(2):428\u201338.","journal-title":"J Diabetes Sci Technol"},{"key":"2180_CR78","unstructured":"Nephrology ISo. Chronic Kidney Disease (CKD) Early Identification and Intervention in Primary Care. 2023."},{"issue":"5s","key":"2180_CR79","first-page":"1","volume":"102","author":"KDIGOKDW Group","year":"2022","unstructured":"Group KDIGOKDW. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in chronic kidney disease. Kidney Int. 2022;102(5s):1\u2013s127.","journal-title":"Kidney Int"},{"key":"2180_CR80","doi-asserted-by":"crossref","first-page":"204201882211124","DOI":"10.1177\/20420188221112490","volume":"13","author":"BJ von Scholten","year":"2022","unstructured":"von Scholten BJ, Kreiner FF, Rasmussen S, Rossing P, Idorn T. The potential of GLP-1 receptor agonists in type 2 diabetes and chronic kidney disease: from randomised trials to clinical practice. Ther Adv Endocrinol Metab. 2022;13:20420188221112490.","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"10365","key":"2180_CR81","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","volume":"400","author":"Consortium","year":"2022","unstructured":"Consortium, NDoPHRSGSiM-AC-RT. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet (London England). 2022;400(10365):1788\u2013801.","journal-title":"Lancet (London England)"},{"issue":"10416","key":"2180_CR82","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1016\/S0140-6736(23)02230-4","volume":"402","author":"HJL Heerspink","year":"2023","unstructured":"Heerspink HJL, Kiyosue A, Wheeler DC, Lin M, Wijkmark E, Carlson G, et al. Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial. Lancet (London England). 2023;402(10416):2004\u201317.","journal-title":"Lancet (London England)"},{"issue":"11","key":"2180_CR83","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1093\/ajh\/hpad066","volume":"36","author":"GL Bakris","year":"2023","unstructured":"Bakris GL, Yang YF, McCabe JM, Liu JR, Tan XJ, Benn VJ, et al. Efficacy and safety of Ocedurenone: Subgroup Analysis of the BLOCK-CKD Study. Am J Hypertens. 2023;36(11):612\u20138.","journal-title":"Am J Hypertens"},{"issue":"5","key":"2180_CR84","doi-asserted-by":"publisher","first-page":"602","DOI":"10.2215\/CJN.0000000000000149","volume":"18","author":"P Sarafidis","year":"2023","unstructured":"Sarafidis P, Agarwal R, Pitt B, Wanner C, Filippatos G, Boletis J, et al. Outcomes with Finerenone in participants with stage 4 CKD and type 2 diabetes: a FIDELITY Subgroup Analysis. Clin J Am Soc Nephrology: CJASN. 2023;18(5):602\u201312.","journal-title":"Clin J Am Soc Nephrology: CJASN"},{"issue":"6","key":"2180_CR85","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1016\/S2213-8587(18)30150-5","volume":"6","author":"J Pearson-Stuttard","year":"2018","unstructured":"Pearson-Stuttard J, Zhou B, Kontis V, Bentham J, Gunter MJ, Ezzati M. Worldwide burden of cancer attributable to diabetes and high body-mass index: a comparative risk assessment. Lancet Diabetes Endocrinol. 2018;6(6):e6\u2013e15.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10352","key":"2180_CR86","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S0140-6736(22)01438-6","volume":"400","author":"GCRF Collaborators","year":"2022","unstructured":"Collaborators GCRF. The global burden of cancer attributable to risk factors, 2010-19: a systematic analysis for the global burden of Disease Study 2019. Lancet (London England). 2022;400(10352):563\u201391.","journal-title":"Lancet (London England)"},{"issue":"2","key":"2180_CR87","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/nri2921","volume":"11","author":"N Ouchi","year":"2011","unstructured":"Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011;11(2):85\u201397.","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"2180_CR88","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.cmet.2017.09.018","volume":"26","author":"M Rios Garcia","year":"2017","unstructured":"Rios Garcia M, Steinbauer B, Srivastava K, Singhal M, Mattijssen F, Maida A, et al. Acetyl-CoA carboxylase 1-Dependent protein acetylation controls breast Cancer metastasis and recurrence. Cell Metab. 2017;26(6):842\u201355e5.","journal-title":"Cell Metab"},{"issue":"12","key":"2180_CR89","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1016\/j.cmet.2023.10.003","volume":"35","author":"AMY Zhang","year":"2023","unstructured":"Zhang AMY, Xia YH, Lin JSH, Chu KH, Wang WCK, Ruiter TJJ, et al. Hyperinsulinemia acts via acinar insulin receptors to initiate pancreatic cancer by increasing digestive enzyme production and inflammation. Cell Metabol. 2023;35(12):2119\u201335e5.","journal-title":"Cell Metabol"},{"issue":"10","key":"2180_CR90","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1111\/liv.12903","volume":"35","author":"H Chettouh","year":"2015","unstructured":"Chettouh H, Lequoy M, Fartoux L, Vigouroux C, Desbois-Mouthon C. Hyperinsulinaemia and insulin signalling in the pathogenesis and the clinical course of hepatocellular carcinoma. Liver Int. 2015;35(10):2203\u201317.","journal-title":"Liver Int"},{"issue":"2","key":"2180_CR91","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.jhep.2023.03.038","volume":"79","author":"F Tacke","year":"2023","unstructured":"Tacke F, Puengel T, Loomba R, Friedman SL. An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH. J Hepatol. 2023;79(2):552\u201366.","journal-title":"J Hepatol"},{"issue":"6","key":"2180_CR92","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, et al. A phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. 2024;390(6):497\u2013509.","journal-title":"N Engl J Med"},{"issue":"1","key":"2180_CR93","doi-asserted-by":"publisher","first-page":"100563","DOI":"10.1016\/j.jhepr.2022.100563","volume":"5","author":"SA Harrison","year":"2023","unstructured":"Harrison SA, Ruane PJ, Freilich B, Neff G, Patil R, Behling C, et al. A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis. JHEP Rep. 2023;5(1):100563.","journal-title":"JHEP Rep"},{"issue":"11","key":"2180_CR94","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1056\/NEJMoa2304286","volume":"389","author":"R Loomba","year":"2023","unstructured":"Loomba R, Sanyal AJ, Kowdley KV, Bhatt DL, Alkhouri N, Frias JP, et al. Randomized, controlled trial of the FGF21 Analogue Pegozafermin in NASH. N Engl J Med. 2023;389(11):998\u20131008.","journal-title":"N Engl J Med"},{"issue":"6","key":"2180_CR95","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","volume":"8","author":"R Loomba","year":"2023","unstructured":"Loomba R, Abdelmalek MF, Armstrong MJ, Jara M, Kj\u00e6r MS, Krarup N, et al. Semaglutide 2\u00b74\u00a0mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8(6):511\u201322.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2180_CR96","unstructured":"A study of tirzepatide (LY3298176). in participants with nonalcoholic steatohepatitis (NASH) (SYNERGY-NASH) [Internet]. 2019. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04166773."},{"issue":"6","key":"2180_CR97","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"79","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6):1542\u201356.","journal-title":"J Hepatol"},{"issue":"1","key":"2180_CR98","doi-asserted-by":"publisher","first-page":"101133","DOI":"10.1016\/j.aohep.2023.101133","volume":"29","author":"ME Rinella","year":"2024","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Ann Hepatol. 2024;29(1):101133.","journal-title":"Ann Hepatol"},{"issue":"4","key":"2180_CR99","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.cmet.2021.01.015","volume":"33","author":"Q Zhang","year":"2021","unstructured":"Zhang Q, Delessa CT, Augustin R, Bakhti M, Colld\u00e9n G, Drucker DJ, et al. The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling. Cell Metab. 2021;33(4):833\u201344e5.","journal-title":"Cell Metab"},{"issue":"12","key":"2180_CR100","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1038\/s42255-023-00931-7","volume":"5","author":"A Liskiewicz","year":"2023","unstructured":"Liskiewicz A, Khalil A, Liskiewicz D, Novikoff A, Grandl G, Maity-Kumar G, et al. Glucose-dependent insulinotropic polypeptide regulates body weight and food intake via GABAergic neurons in mice. Nat Metab. 2023;5(12):2075\u201385.","journal-title":"Nat Metab"},{"issue":"12","key":"2180_CR101","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/nrendo.2010.187","volume":"6","author":"KM Habegger","year":"2010","unstructured":"Habegger KM, Heppner KM, Geary N, Bartness TJ, DiMarchi R, Tsch\u00f6p MH. The metabolic actions of glucagon revisited. Nat Rev Endocrinol. 2010;6(12):689\u201397.","journal-title":"Nat Rev Endocrinol"},{"issue":"10401","key":"2180_CR102","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/S0140-6736(23)01053-X","volume":"402","author":"J Rosenstock","year":"2023","unstructured":"Rosenstock J, Frias J, Jastreboff AM, Du Y, Lou J, Gurbuz S, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet (London England). 2023;402(10401):529\u201344.","journal-title":"Lancet (London England)"},{"issue":"6","key":"2180_CR103","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa2301972","volume":"389","author":"AM Jastreboff","year":"2023","unstructured":"Jastreboff AM, Kaplan LM, Fr\u00edas JP, Wu Q, Du Y, Gurbuz S, et al. Triple\u2013hormone-receptor agonist retatrutide for obesity \u2014 a phase 2 trial. N Engl J Med. 2023;389(6):514\u201326.","journal-title":"N Engl J Med"},{"issue":"10403","key":"2180_CR104","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/S0140-6736(23)01127-3","volume":"402","author":"VR Aroda","year":"2023","unstructured":"Aroda VR, Aberle J, Bardtrum L, Christiansen E, Knop FK, Gabery S, et al. Efficacy and safety of once-daily oral semaglutide 25\u00a0mg and 50\u00a0mg compared with 14\u00a0mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial. Lancet (London England). 2023;402(10403):693\u2013704.","journal-title":"Lancet (London England)"},{"issue":"10400","key":"2180_CR105","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/S0140-6736(23)01302-8","volume":"402","author":"JP Frias","year":"2023","unstructured":"Frias JP, Hsia S, Eyde S, Liu R, Ma X, Konig M, et al. Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study. Lancet (London England). 2023;402(10400):472\u201383.","journal-title":"Lancet (London England)"},{"issue":"1","key":"2180_CR106","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40271-012-0001-0","volume":"6","author":"J Schabert","year":"2013","unstructured":"Schabert J, Browne JL, Mosely K, Speight J. Social stigma in diabetes: a framework to understand a growing problem for an increasing epidemic. Patient. 2013;6(1):1\u201310.","journal-title":"Patient"},{"issue":"1","key":"2180_CR107","doi-asserted-by":"publisher","first-page":"e13642","DOI":"10.1111\/obr.13642","volume":"25","author":"S Nutter","year":"2024","unstructured":"Nutter S, Eggerichs LA, Nagpal TS, Ramos Salas X, Chin Chea C, Saiful S, et al. Changing the global obesity narrative to recognize and reduce weight stigma: a position statement from the World Obesity Federation. Obes Rev. 2024;25(1):e13642.","journal-title":"Obes Rev"},{"issue":"11","key":"2180_CR108","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.7326\/M22-2360","volume":"176","author":"C Albury","year":"2023","unstructured":"Albury C, Webb H, Stokoe E, Ziebland S, Koshiaris C, Lee JJ, et al. Relationship between Clinician Language and the success of behavioral weight loss interventions: a mixed-methods cohort study. Ann Intern Med. 2023;176(11):1437\u201347.","journal-title":"Ann Intern Med"},{"key":"2180_CR109","volume-title":"Type 1 diabetes mellitus estimates in children and adults","author":"GD Ogle","year":"2022","unstructured":"Ogle GD, Wang F, Gregory GA, Maniam J. Type 1 diabetes mellitus estimates in children and adults. Brussels, Belgium: International Diabetes Federation; 2022."},{"issue":"10","key":"2180_CR110","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S2213-8587(22)00218-2","volume":"10","author":"GA Gregory","year":"2022","unstructured":"Gregory GA, Robinson TIG, Linklater SE, Wang F, Colagiuri S, de Beaufort C, et al. Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study. Lancet Diabetes Endocrinol. 2022;10(10):741\u201360.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2180_CR111","doi-asserted-by":"publisher","first-page":"737964","DOI":"10.3389\/fimmu.2021.737964","volume":"12","author":"LM Quinn","year":"2021","unstructured":"Quinn LM, Wong FS, Narendran P. Environmental determinants of type 1 diabetes: from Association to proving causality. Front Immunol. 2021;12:737964.","journal-title":"Front Immunol"},{"issue":"9","key":"2180_CR112","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1007\/s00125-023-05953-0","volume":"66","author":"S Hummel","year":"2023","unstructured":"Hummel S, Carl J, Friedl N, Winkler C, Kick K, Stock J, et al. Children diagnosed with presymptomatic type 1 diabetes through public health screening have milder diabetes at clinical manifestation. Diabetologia. 2023;66(9):1633\u201342.","journal-title":"Diabetologia"},{"key":"2180_CR113","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1126\/scitranslmed.abc8980","volume":"13","author":"EK Sims","year":"2021","unstructured":"Sims EK, Bundy BN, Stier K, Serti E, Lim N, Long SA, et al. Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. Sci Transl Med. 2021;13:583.","journal-title":"Sci Transl Med"},{"issue":"23","key":"2180_CR114","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1056\/NEJMoa2308743","volume":"389","author":"EL Ramos","year":"2023","unstructured":"Ramos EL, Dayan CM, Chatenoud L, Sumnik Z, Simmons KM, Szypowska A, et al. Teplizumab and \u03b2-Cell function in newly diagnosed type 1 diabetes. N Engl J Med. 2023;389(23):2151\u201361.","journal-title":"N Engl J Med"},{"issue":"1","key":"2180_CR115","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1007\/s00125-023-06025-z","volume":"67","author":"J Elliott","year":"2024","unstructured":"Elliott J, Sloan G, Stevens L, Selvarajah D, Cruccu G, Gandhi RA, et al. Female sex is a risk factor for painful diabetic peripheral neuropathy: the EURODIAB prospective diabetes complications study. Diabetologia. 2024;67(1):190\u20138.","journal-title":"Diabetologia"},{"issue":"10353","key":"2180_CR116","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/S0140-6736(22)01472-6","volume":"400","author":"S Tesfaye","year":"2022","unstructured":"Tesfaye S, Sloan G, Petrie J, White D, Bradburn M, Julious S, et al. Comparison of Amitriptyline supplemented with Pregabalin, Pregabalin supplemented with Amitriptyline, and duloxetine supplemented with Pregabalin for the treatment of diabetic peripheral neuropathic pain (OPTION-DM): a multicentre, double-blind, randomised crossover trial. Lancet (London England). 2022;400(10353):680\u201390.","journal-title":"Lancet (London England)"},{"key":"2180_CR117","doi-asserted-by":"publisher","first-page":"109063","DOI":"10.1016\/j.diabres.2021.109063","volume":"186","author":"D Ziegler","year":"2022","unstructured":"Ziegler D, Tesfaye S, Spallone V, Gurieva I, Al Kaabi J, Mankovsky B, et al. Screening, diagnosis and management of diabetic sensorimotor polyneuropathy in clinical practice: International expert consensus recommendations. Diabetes Res Clin Pract. 2022;186:109063.","journal-title":"Diabetes Res Clin Pract"},{"issue":"9","key":"2180_CR118","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.2174\/1871530320666200506081407","volume":"20","author":"MR El-Nahas","year":"2020","unstructured":"El-Nahas MR, Elkannishy G, Abdelhafez H, Elkhamisy ET, El-Sehrawy AA. Oral alpha Lipoic Acid Treatment for Symptomatic Diabetic Peripheral Neuropathy: a Randomized double-blinded placebo-controlled study. Endocr Metab Immune Disord Drug Targets. 2020;20(9):1531\u20134.","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"issue":"1s","key":"2180_CR119","doi-asserted-by":"publisher","first-page":"177s","DOI":"10.18433\/jpps30100","volume":"21","author":"N Nguyen","year":"2018","unstructured":"Nguyen N, Takemoto JK. A case for alpha-lipoic acid as an Alternative Treatment for Diabetic Polyneuropathy. J Pharm Pharm Sci. 2018;21(1s):177s\u201391s.","journal-title":"J Pharm Pharm Sci"},{"issue":"9","key":"2180_CR120","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.2337\/dc11-0503","volume":"34","author":"D Ziegler","year":"2011","unstructured":"Ziegler D, Low PA, Litchy WJ, Boulton AJ, Vinik AI, Freeman R, et al. Efficacy and safety of antioxidant treatment with \u03b1-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care. 2011;34(9):2054\u201360.","journal-title":"Diabetes Care"},{"issue":"10","key":"2180_CR121","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1055\/s-2008-1065351","volume":"116","author":"H Stracke","year":"2008","unstructured":"Stracke H, Gaus W, Achenbach U, Federlin K, Bretzel RG. Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study. Experimental and clinical endocrinology & diabetes: official journal. German Soc Endocrinol [and] German Diabetes Association. 2008;116(10):600\u20135.","journal-title":"German Soc Endocrinol [and] German Diabetes Association"},{"issue":"3","key":"2180_CR122","doi-asserted-by":"publisher","first-page":"634","DOI":"10.2337\/dc21-0601","volume":"45","author":"CA Celis-Morales","year":"2022","unstructured":"Celis-Morales CA, Franz\u00e9n S, Eeg-Olofsson K, Naucl\u00e9r E, Svensson AM, Gudbjornsdottir S, et al. Type 2 diabetes, Glycemic Control, and their Association with Dementia and its major subtypes: findings from the Swedish National Diabetes Register. Diabetes Care. 2022;45(3):634\u201341.","journal-title":"Diabetes Care"},{"issue":"8","key":"2180_CR123","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1007\/s00125-023-05930-7","volume":"66","author":"J Hu","year":"2023","unstructured":"Hu J, Fang M, Pike JR, Lutsey PL, Sharrett AR, Wagenknecht LE, et al. Prediabetes, intervening diabetes and subsequent risk of dementia: the atherosclerosis risk in communities (ARIC) study. Diabetologia. 2023;66(8):1442\u20139.","journal-title":"Diabetologia"},{"issue":"1","key":"2180_CR124","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/dom.14866","volume":"25","author":"T Sugimoto","year":"2023","unstructured":"Sugimoto T, Tokuda H, Miura H, Kawashima S, Ando T, Kuroda Y, et al. Cross-sectional association of metrics derived from continuous glucose monitoring with cognitive performance in older adults with type 2 diabetes. Diabetes Obes Metab. 2023;25(1):222\u20138.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"2180_CR125","doi-asserted-by":"publisher","first-page":"e234","DOI":"10.1210\/clinem\/dgad442","volume":"109","author":"R Li","year":"2023","unstructured":"Li R, Geng T, Li L, Lu Q, Li R, Chen X, et al. Associations of glucose metabolism status with brain macrostructure and microstructure: findings from the UK Biobank. J Clin Endocrinol Metab. 2023;109(1):e234\u2013e42.","journal-title":"J Clin Endocrinol Metab"},{"key":"2180_CR126","doi-asserted-by":"publisher","first-page":"103455","DOI":"10.1016\/j.nicl.2023.103455","volume":"39","author":"J Monereo-S\u00e1nchez","year":"2023","unstructured":"Monereo-S\u00e1nchez J, Jansen JFA, K\u00f6hler S, van Boxtel MPJ, Backes WH, Stehouwer CDA, et al. The association of prediabetes and type 2 diabetes with hippocampal subfields volume: the Maastricht study. Neuroimage Clin. 2023;39:103455.","journal-title":"Neuroimage Clin"},{"issue":"2","key":"2180_CR127","doi-asserted-by":"publisher","first-page":"549","DOI":"10.2337\/dc20-1862","volume":"44","author":"J Lu","year":"2021","unstructured":"Lu J, Wang C, Shen Y, Chen L, Zhang L, Cai J, et al. Time in Range in Relation to all-cause and Cardiovascular Mortality in patients with type 2 diabetes: a prospective cohort study. Diabetes Care. 2021;44(2):549\u201355.","journal-title":"Diabetes Care"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-024-02180-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-024-02180-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-024-02180-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T16:04:12Z","timestamp":1710864252000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-024-02180-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,19]]},"references-count":127,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2180"],"URL":"https:\/\/doi.org\/10.1186\/s12933-024-02180-8","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,19]]},"assertion":[{"value":"20 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"OS (Oliver Schnell) is the founder and CEO of Sciarc and reports consulting, speaking, or serving on advisory boards for AstraZeneca, Bayer, Boehringer Ingelheim, Lilly, MSD, Mundipharma, Novo Nordisk, Roche, Sanofi, and W\u00f6rwag Pharma. KBK (Katharine Barnard-Kelly) is founder and shareholder at Spotlight-AQ Ltd. KBK has received research support from Dexcom, Embecta, JDRF, Novo Nordisk and Roche Diabetes Care, and honoraria from Sanofi. TB (Tadej Battelino) has served on the advisory boards of Abbott, Boehringer Ingelheim, Dreamed Diabetes, Eli Lilly and Company, Indigo Diabetes, Medtronic, Novo Nordisk, and Sanofi. TB has received speaker\u2019s bureau honoraria from Abbott, Eli Lilly and Company, Medtronic, Novo Nordisk, Roche, and Sanofi. The University Medical Center has received research grant support from Abbott, GluSense, Medtronic, Novo Nordisk, Sandoz, Sanofi, and Zealand Pharma. AC (Antonio Ceriello) reports consulting and speaking for Bayer, Berlin-Chemie, Eli Lilly and Company, Guidotti, Merck, Novo Nordisk, Roche Diagnostics and Sanofi. HEL (Helena Elding Larsson) declares that she has no competing interests. BFF (Beatriz Fern\u00e1ndez-Fern\u00e1ndez) has received grants from AstraZeneca and Esteve and consultancy or speaker fees or travel support from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly and Company, Menarini, Novo Nordisk, and Mundipharma. JPF (Juan-Pablo Frias) is employee and stockholder of Biomea Fusion, Inc. JPF has received research support from Akero, Altimmune, Boehringer Ingelheim, 89bio, Eli Lilly and Company, Intercept, IONIS, Janssen, Madrigal, Merck, NorthSea Therapeutics, Novartis, Novo Nordisk, Oramed, Pfizer, Sanofi, and Shionogi. JPF has also served as a consultant and on the advisory boards of Akero, Altimmune, Biomea Fusion, Boehringer Ingelheim, Carmot Therapeutics, Echosens, 89bio, Eli Lilly and Company, Gilead, Intercept, Metacrine, Merck, Novo Nordisk, Pfizer, Sanofi, and on the speaker\u2019s bureau for Eli Lilly and Company. TF (Thomas Forst) has been a member of the speaker panel of Amarin, AstraZeneca, Boehringer Ingelheim, Berlin-Chemie, Cipla, Daiichi-Sankyo, Eli Lilly and Company, Fortbildungskolleg, MSD, Novartis, Novo Nordisk, Sanofi, Santis, and of the advisory panel of Atrogi, Bayer, Cipla, Diabetes-Akademie Bad Mergentheim e.V., Eli Lilly and Company, Eyesense, Fortbildungskolleg, Novo Nordisk, Pfizer, reMYND, Roche and Sanofi. JRG (James R. Gavin III) has served on the advisory boards of Abbott Diabetes Care and Embecta, and on the speaker\u2019s bureaus of Boehringer Ingelheim and Eli Lilly and Company. FG (Francesco Giorgino) has served on the advisory boards of AstraZeneca, Eli Lilly and Company, Novo Nordisk, Roche Diabetes Care, Sanofi and as a consultant to AstraZeneca, Boehringer Ingelheim, LifeScan, Medimmune, Medtronic, Merck Sharp & Dohme, Roche Diabetes Care and Sanofi. FG has also received research support from Eli Lilly and Company and Roche Diabetes Care. PHG (Per-Henrik Groop) has received lecture honoraria from Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly and Company, EloWater, Genzyme, Medscape, MSD, Mundipharma, Novartis, Novo Nordisk, Peer Voice, Sanofi and Sciarc. PHG also serves as an advisory board member for AbbVie, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly and Company, Medscape, MSD, Mundipharma, Novartis, Novo Nordisk, and Sanofi. HJLH (Hiddo J.L. Heerspink) declares that he has no competing interests. SH (Stephan Herzig) declares that he has no competing interests. MH (Michael Hummel) declares that he has no competing interests. GH (George Huntley) declares that he has no competing interests. MI (Mahmoud Ibrahim) has consultancy agreement with and received speaker honoraria from Boehringer Ingelheim, Medtronic, Novo Nordisk, and Pfizer. BI (Baruch Itzhak) has received honoraria or consulting fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, and Novo Nordisk and speaking fees from Abbott, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Novo Nordisk, Roche, and Sanofi. SJ (Stephan Jacob) declares that he has no competing interests. LJ (Linong Ji) declares that he has no competing interests. MK (Mikhail Kosiborod) reports consulting or advisory board participation for 35Pharma, Alnylam Pharmaceuticals, Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Dexcom, Eli Lilly and Company, Esperion Therapeutics, Janssen Pharmaceuticals, Lexicon Pharmaceuticals, Merck (Diabetes and Cardiovascular), Novo Nordisk, Pharmacosmos, Pfizer, scPharmaceuticals, Sanofi, Structure Therapeutics, Vifor Pharma and Youngene Therapeutics. MK has also received honoraria from AstraZeneca, Boehringer Ingelheim and Novo Nordisk, and research grants from AstraZeneca, Boehringer Ingelheim and Pfizer. NL (Nebosja Lalic) declares that he has no competing interests. SM (Sofia Macieira) is employee of Sciarc. RM (Rayaz A.\u00a0Malik) has served on the advisory panel and received honoraria for speaking for Eli Lilly and Company, Novo Nordisk, Proctor & Gamble, Sanofi Aventis, and Viatris. RM has also received research funding for studies from Novo Nordisk and Proctor & Gamble. BM (Boris Mankovsky) has served on advisory boards and received speaking fees from AstraZeneca, Bayer, Boehringer Ingelheim, Novartis, Novo Nordisk, Sanofi, Servier, and W\u00f6rwag Pharma. NM (Nikolaus Marx) has received research grants from Boehringer Ingelheim and MSD, speaking fees form Amgen, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Eli Lilly and Company, MSD, Novo Nordisk, and Sanofi-Aventis and has served or serves on the advisory board of Amgen, Bayer, BMS, Boehringer Ingelheim, MSD, Novo Nordisk, and Sanofi-Aventis. CM (Chantal Mathieu) serves or has served on the advisory panel for ActoBio Therapeutics, Avotres, AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Imcyse, Insulet, Mannkind, Medtronic, Merck Sharp and Dohme Ltd., Novartis, Novo Nordisk, Pfizer, Sandoz, Sanofi, Roche, Vertex and Zealand Pharma. CM serves or has served on the speakers\u2019 bureau for AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Novartis Novo Nordisk, and Sanofi. Financial compensation for these activities has been received by KU Leuven. KU Leuven has received research support for CM from ActoBio Therapeutics, Imcyse, Medtronic, Novo Nordisk, and Sanofi. TM (Timo M\u00fcller) reports having received honoraria or research support from AstraZeneca, Berlin-Chemie, Eli Lilly and Company, Merck, Mercodia, MSD, Novo Nordisk, and Sanofi Aventis in the past 3 years. KR (Kausik Ray) has served as a consultant for Abbott, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cargene Therapeutics, Cleerly Health, CRISPR Therapeutics, CSL Behring, Eli Lilly and Company, EmendoBio, Esperion Therapeutics, Kowa Pharmaceutics, New Amsterdam Pharma, Novartis, Novo Nordisk, Pfizer, Regeneron, Resverlogix, Sanofi, Scribe Thearapeutics, Silence Therapeutics, VAXXINITY, and Viatris. KR reports having received research grants from Amgen, Daiichi Sankyo, MSD, Pfizer, Regeneron, Sanofi and Ultragenix. HR (Helena W. Rodbard) declares that she has no competing interests. PR (Peter Rossing) has received honoraria for consultancy and\/or speaking fees (to his institution) from AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly and Company, Gilead, MSD, Novo Nordisk, and Sanofi Aventis and research grants from AstraZeneca, Bayer, and Novo Nordisk. LR (Lars Ryd\u00e9n) declares that he has no competing interests. PMSD (Petra-Maria Schumm-Draeger) declares that she has no competing interests. PS (Peter Schwarz) declares that he has no competing interests. JS (Jan \u0160krha) declares that he has no competing interests. FS (Frank Snoek) has received research support from Sanofi, consulting fees from Abbott, LifeScan, Roche, and Sanofi, and has served on a speaker\u2019s bureau for Abbott and Sanofi. FT (Frank Tacke) declares that work in his lab has been supported by research grants from AstraZeneca, Gilead, and MSD. BT (Bruce Taylor) is employee of Dexcom. BTJ (Britta Tendal Jeppesen) declares that she has no competing interests. ST (Solomon Tesfaye) reports honoraria for educational meetings from Astellas Pharma, AstraZeneca, Berlin-Chemie, Eva Pharma, Gr\u00fcnenthal, Hikma, Merck, Nevro, Novo Nordisk, P&G Health, Viatris, and W\u00f6rwag Pharma; consulting fees from Angelini, AstraZeneca, Bayer, Gr\u00fcnenthal, Mitsubishi Tanabe Pharma, Merz, NeuroPN, Nevro, Viatris and W\u00f6rwag Pharma; unrestricted research grants from Proctor and Gamble, Viatris and Withings. PT (Pinar Topsever) has received honoraria or consulting fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, and LifeScan, and has served on the speaker\u2019s bureau for AstraZeneca. PT received grant\/research support from PCDE, made possible by corporate sponsorship from AstraZeneca, Eli Lilly, Novo Nordisk, and Roche Diagnostics; the sponsors had no input into the study protocols. TV (Tina Vilsb\u00f8ll) has served on scientific advisory panels, been part of speaker\u2019s bureaus, and served as a consultant to and\/or received research support from Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Gilead, GSK, Mundipharma, MSD\/Merck, Novo Nordisk, Sanofi, and Sun Pharmaceuticals. XY (Xuefeng Yu) declares that he has no competing interests. ES (Eberhard Standl) declares that he has no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"104"}}